Lack of Knowledge About Hepatitis C Infection Rates Among Patients With Inherited Coagulation Disorders in Countries Under the Eastern Mediterranean Region Office of WHO (EMRO): A Meta-Analysis

Abstract

ContextHepatitis C virus (HCV) infection is a public health problem. HCV alone is responsible for 90% cases of acute hepatitis among multiply transfused patients who are at risk of cirrhosis and hepatocellular carcinoma (HCC).ObjectivesTo provide a clear picture of available data, we performed a systematic review of the epidemiological characteristics of HCV infection among patients with inherited coagulation disorders in the countries under the Eastern Mediterranean Region Office (EMRO).Evidence AcquisitionMeta-analysis was carried out on the basis of results of electronic and manual search. This analysis included studies in English, French, and Persian that met with the following criteria: (1) appropriate study design: cross-sectional, case-control, and cohort; (2) studies reporting HCV prevalence according to enzyme immune assay; (3) studies in which the sample population was enrolled from EMRO countries. According to the results of the heterogeneity tests, we used fixed-effect/random-effect model for our meta-analysis, with the “Metan” command.ResultsWe included 30 studies, most of which were from Iran. The mean age of the subjects ranged from 13 to 27.1 years. The majority of the patients were male (range, 81% to 100%). The pooled estimate of HCV infection among patients with inherited coagulation disorders was 48.07% (95% confidence interval [CI], range: 27.39–55.68) in Iran, 36.03% (95% CI, range: 4.466–67.598) in Pakistan, and 48.27% (95% CI, range: 36.12–60.43) in all the EMRO countries taken together.ConclusionsIn Iran and other EMRO countries, the HCV infection rate among patients with inherited coagulation disorders is high. Our study shows that there is a lack of knowledge about infections in such patients in most of the EMRO countries. It is the responsibility of health-policy makers to address this knowledge gap and provide safe and adequate treatment for patients in high-risk groups.

Co-Infection of the Hepatitis C Virus With Other Blood-Borne and Hepatotropic Viruses Among Hemophilia Patients in Poland

“…Yet, the prevalence is significantly lower in southern Iran than in northern and central Iran. The overall prevalence of hepatitis C among hemophiliacs in Iran is said to be 40.8% (23). …”

The Efficiency of Hepatitis C Virus Core Antigen Test in the Diagnosis of Hepatitis C Infection

“…There are approximately 200 million individuals infected with HCV throughout the world. Moreover, HCV is considered as the most important reason for liver diseases in both developed and developing countries (3). HCV prevalence varies greatly in geographic distribution depending on the level of development of the country.…”

Molecular Tracing of Hepatitis C Virus Genotype 1 Isolates in Iran: A NS5B Phylogenetic Analysis with Systematic Review

“…It seems that this similarity is more likely among Iranian patients with inherited congenital bleeding disorder such as hemophilia. The prevalence of HCV among Iranian hemophilia patients is high, as it is said that the overall prevalence in these Iranian patients group is 40.8%, with a range from 13.3% to 80.5% (8, 56). It is noteworthy that in the 1980s, with the arrival of blood and blood products from France to Iran, a large number of patients, particularly hemophiliac patients, were infected with HIV and HCV.…”

“…The prevalence of HCV infection in Iran is estimated to be less than 0.5% (6, 7). It is well established that hepatitis C contributes to the increasing risk of fatal-related diseases including cirrhosis and hepatocellular carcinoma (HCC) (8, 9). In spite of numerous progressions in hepatitis C treatment, the high prevalence of hepatitis C in developing countries is still a major concern (10).…”